Coxib-class non-steroidal anti-inflammatory drug

Equioxx, like other NSAIDS, may cause some side effects. Serious side effects associated with NSAID therapy in horses can occur with or without warning. The most common side effects associated with Equioxx therapy involve the tongue, lips and skin of the mouth and face (erosions and ulcers of the mucosa and skin) and the kidney. Gastrointestinal, kidney and liver problems have also been reported with other NSAIDs. Look for the following side effects that may indicate your horse is having a problem with Equioxx or may have another medical problem:

Deramaxx tablets, like all other drugs, may cause some side effects in individual dogs. These are normally mild, but rare serious side effects have been reported in dogs taking non-steroidal anti-inflammatory drugs (NSAIDs) including Deramaxx. Serious side effects can, in rare situations, result in death. It is important to stop the medication and contact your veterinarian immediately if you think your dog may have a medical problem or side effect while on Deramaxx tablets. If you have additional questions about possible side effects, talk with your veterinarian or call 1-800-332-2761.

The VIGOR (Vioxx Gastrointestinal Outcomes Research) trial, "which was the making of Merck's drug rofecoxib (Vioxx)," [38] was at the center of a dispute about the ethics of medical journals. VIGOR trial,1 was a trial in which over 8000 patients were randomized to receive either naproxen or rofecoxib (Vioxx), a Cox-2 inhibitor that Merck hoped would have fewer gastrointestinal side effects." [38] Both publications concluded that COX-2 specific NSAIDs were associated with significantly fewer adverse gastrointestinal effects. In the CLASS trial comparing Celebrex 800 mg/day to ibuprofen 2400 mg/day and diclofenac 150 mg/day for osteoarthritis or rheumatoid arthritis for six months, Celebrex was associated with significantly fewer upper gastrointestinal complications (% vs. %, P=), with no significant difference in incidence of cardiovascular events in patients not taking aspirin for cardiovascular prophylaxis .

The mechanisms responsible for the increased cardiovascular risk associated with coxibs and tNSAIDs are not well understood and are likely to be multifactorial. It seems likely that relative levels of nitric oxide, prostacyclin (PGI 2 ) and thromboxane A2 (TxA 2 ) will play an important role in endothelial homeostasis. Prostaglandins and TxA 2 are derived from arachidonic acid (Figure 1). PGH 2 is generated by the activity of cyclooxygenases from arachidonic acid via PGG 2 . PGH 2 acts as the substrate for specific synthases, the products of which are TxA 2 , PGI 2 , PGD 2 , PGE 2 and PGF 2α (Figure 1).

Coxib-class non-steroidal anti-inflammatory drug

coxib-class non-steroidal anti-inflammatory drug

The mechanisms responsible for the increased cardiovascular risk associated with coxibs and tNSAIDs are not well understood and are likely to be multifactorial. It seems likely that relative levels of nitric oxide, prostacyclin (PGI 2 ) and thromboxane A2 (TxA 2 ) will play an important role in endothelial homeostasis. Prostaglandins and TxA 2 are derived from arachidonic acid (Figure 1). PGH 2 is generated by the activity of cyclooxygenases from arachidonic acid via PGG 2 . PGH 2 acts as the substrate for specific synthases, the products of which are TxA 2 , PGI 2 , PGD 2 , PGE 2 and PGF 2α (Figure 1).

Media:

coxib-class non-steroidal anti-inflammatory drugcoxib-class non-steroidal anti-inflammatory drugcoxib-class non-steroidal anti-inflammatory drugcoxib-class non-steroidal anti-inflammatory drugcoxib-class non-steroidal anti-inflammatory drug

http://buy-steroids.org